Welcome to our dedicated page for Logiq news (Ticker: LGIQ), a resource for investors and traders seeking the latest updates and insights on Logiq stock.
Logiq, Inc. (LGIQ) generates news across two distinct but connected themes: its legacy role in digital consumer acquisition and its newer focus on health, biotech, medical devices, and animal health. Historically, the company has issued updates on its AI-powered programmatic advertising platform, including fraud detection capabilities, client wins, and corporate initiatives related to its DataLogiq (DLQ) business and proposed SPAC merger with Abri SPAC I, Inc.
More recent announcements emphasize Logiq's strategic shift toward the medical field. Investors and observers can find coverage of the definitive agreement to acquire MedLab Essentials, LLC, a company focused on cell and gene therapy and cell-based therapies for challenging cancers, age-related diseases, and longevity applications. News also includes details of the definitive agreement to acquire EVIMATE, a developer of AI-enabled vital sign monitoring and remote patient monitoring devices.
Another important area of Logiq news involves its veterinarian division, associated with Amino Medic Ltd., and the launch of AVR BIOVET™, a copper-based organic feed additive designed to support growth, immune function, and overall health in animals. Company communications discuss the product's composition, testing, and potential role in animal health and organic production.
On this page, readers can review press releases related to acquisitions, business model updates, capital markets plans, SPAC-related milestones, and product introductions in both digital advertising and health-focused lines of business. For those tracking LGIQ, the news flow provides insight into how the company describes its transition from e-commerce and ad tech toward cell and gene therapy, longevity medicine, medical devices, and animal health solutions.
Logiq Inc (OTC:LGIQ) has announced the launch of AVR BIOVET™, a new organic feed additive through its veterinary division MedLabs/Amino Medic The product features nano particles of copper, essential amino acids, vitamins, and probiotics designed to maximize growth potential and improve animal health.
AVR BIOVET™ aims to supplement or replace antibiotics in breeding cycles, making products organic and Glatt Kosher. In testing with pig farms by BIOTEC Group, the product showed an 80% survival rate among early-born piglets that typically have only a 10% survival rate. The product is bioavailable, non-accumulating, and eliminates from the body within 72 hours.
The company is seeking FDA and USDA approvals before manufacturing. Additionally, Logiq announced the initiation of a CEO search, with Brent Suen transitioning from his role. The R&D team, led by Dr. Mark Litvak in Tel Aviv, will continue developing solutions for both animal and human health applications.
Logiq, Inc. (OTC PINK:LGIQ) has announced a definitive agreement to acquire EVIMATE, a medical device innovation company, for $5 million. This acquisition marks Logiq's entry into the medical device sector. EVIMATE specializes in advanced vital sign monitoring products that utilize AI technology for comprehensive health metric tracking and predictive analytics.
EVIMATE's solution includes next-generation devices and a user-friendly app that continuously monitors key health indicators such as temperature, heart rate, ECG, blood pressure, oxygen levels, and glucose levels. The system is designed for Remote Patient Monitoring (RPM), providing real-time insights and alerts to healthcare providers, caregivers, and family members.
Additionally, EVIMATE has developed an automotive healthcare system for monitoring driver vitals, featuring sensors in the driver's seat and steering wheel to collect vital signs like heart functions, respiratory rate, stress level, and blood oxygen level. All devices mentioned will require FDA regulatory approvals and additional patent filings for IP protection.
Logiq, Inc. (OTC:LGIQ) has announced a definitive agreement to acquire MedLab Essentials, , a leader in cell and gene therapy innovation, in a deal valued at $100 million. The acquisition will be executed through a share exchange, with MedLab becoming a wholly owned subsidiary of Logiq. Key highlights include:
1. Logiq shareholders will retain 15% post-transaction
2. The combined entity aims to uplist to Nasdaq, CBOE, or NYSE
3. A substantial capital raise is planned by the end of 2024
4. This marks Logiq's first step in a series of biotech acquisitions targeting a cumulative value over $750 million
This strategic move signifies Logiq's diversification into the biotech sector, particularly focusing on cell and gene therapy assets.
Logiq has signed a binding letter of intent to acquire MedLab Essentials for $100 million in a share exchange deal. MedLab will become a wholly-owned subsidiary, with its executives joining Logiq's senior management.
This acquisition diversifies Logiq into the biotech sector and aims for a Nasdaq, CBOE, or NYSE uplisting by Q3 2024. Post-transaction, Logiq shareholders will retain 15% of the company. This is part of a broader strategy to expand into biotech and cell and gene therapy, targeting a cumulative value exceeding $750 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Logiq (LGIQ)?
What is the market cap of Logiq (LGIQ)?
